

Press Release

For Immediate Release

Glenmark announces launch of Hydrocortisone Butyrate cream in the US

Glenmark is entitled to 180 days of exclusivity as it is the first generic company to file an ANDA for the product.

December 9, 2013: Glenmark Generics Inc., USA, the subsidiary of Glenmark Generics Limited, announces the exclusive launch of Hydrocortisone Butyrate cream USP, 0.1% in the United States. The Company received approval from the United States Food and Drug Administration (U.S. FDA) for Abbreviated New Drug Application (ANDA) for its generic version of Locoid Lipocream® on September 27, 2013.

Glenmark is entitled to 180 days of exclusivity with respect to its Hydrocortisone Butyrate cream, as it is the first generic company to file an ANDA for the product.

Hydrocortisone Butyrate cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in adults and the treatment of mild to moderate atopic dermatitis in patients 3 months to 18 years of age. According to IMS Health sales data for the 12 month period ending September 2013, Hydrocortisone Butyrate cream garnered annual sales of approximately USD 36.8 million.

Glenmark's current portfolio consists of 90 products authorized for distribution in the U.S. marketplace and 56 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

About Glenmark Generics Limited

Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America and developing an EU presence. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 80 countries, including the US, various countries in the EU, South America and India.

For further information, please contact:

Jason D'Souza / Rajdeep Barooah
Glenmark, Mumbai, India Tel: [+91 22] 40189919/984
Email: corpcomm@glenmarkpharma.com